Prognostic impact of baseline serum C‐reactive protein in patients with metastatic renal cell carcinoma (RCC) treated with sunitinib

To evaluate the impact of baseline serum C‐reactive protein (CRP) level on outcome in patients with metastatic renal cell carcinoma (mRCC) treated with sunitinib.

[1]  S. Urakami,et al.  Prognostic impact of pretreatment C-reactive protein for patients with metastatic renal cell carcinoma treated with tyrosine kinase inhibitors , 2013, International Journal of Clinical Oncology.

[2]  S. Baba,et al.  C‐reactive protein as a prognostic marker for advanced renal cell carcinoma treated with sunitinib , 2012, International journal of urology : official journal of the Japanese Urological Association.

[3]  M. Yao,et al.  C-reactive protein in patients with advanced metastatic renal cell carcinoma: Usefulness in identifying patients most likely to benefit from initial nephrectomy , 2012, BMC Cancer.

[4]  John V Heymach,et al.  Prognostic or predictive plasma cytokines and angiogenic factors for patients treated with pazopanib for metastatic renal-cell cancer: a retrospective analysis of phase 2 and phase 3 trials. , 2012, The Lancet. Oncology.

[5]  M. Pencina,et al.  On the C‐statistics for evaluating overall adequacy of risk prediction procedures with censored survival data , 2011, Statistics in medicine.

[6]  R. Figlin,et al.  Prognostic factors for progression-free and overall survival with sunitinib targeted therapy and with cytokine as first-line therapy in patients with metastatic renal cell carcinoma. , 2011, Annals of oncology : official journal of the European Society for Medical Oncology.

[7]  K. Ogan,et al.  Absolute preoperative C-reactive protein predicts metastasis and mortality in the first year following potentially curative nephrectomy for clear cell renal cell carcinoma. , 2010, The Journal of urology.

[8]  Wanling Xie,et al.  Prognostic factors for overall survival in patients with metastatic renal cell carcinoma treated with vascular endothelial growth factor-targeted agents: results from a large, multicenter study. , 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[9]  Michael B Atkins,et al.  Resistance to targeted therapy in renal-cell carcinoma. , 2009, The Lancet. Oncology.

[10]  Xin Huang,et al.  Overall Survival and Updated Results for Sunitinib Compared With Interferon Alfa in Patients With Metastatic Renal Cell Carcinoma , 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[11]  R. Motzer,et al.  Efficacy of everolimus in advanced renal cell carcinoma: a double-blind, randomised, placebo-controlled phase III trial , 2008, The Lancet.

[12]  P. Royston,et al.  Interactions between treatment and continuous covariates: a step toward individualizing therapy. , 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[13]  Bohuslav Melichar,et al.  Bevacizumab plus interferon alfa-2a for treatment of metastatic renal cell carcinoma: a randomised, double-blind phase III trial , 2007, The Lancet.

[14]  David McDermott,et al.  Temsirolimus, interferon alfa, or both for advanced renal-cell carcinoma. , 2007, The New England journal of medicine.

[15]  R. Figlin,et al.  Sunitinib versus interferon alfa in metastatic renal-cell carcinoma. , 2007, The New England journal of medicine.

[16]  Apurva A Desai,et al.  Sorafenib in advanced clear-cell renal-cell carcinoma. , 2007, The New England journal of medicine.

[17]  Y. Komai,et al.  Increased preoperative serum C‐reactive protein level predicts a poor prognosis in patients with localized renal cell carcinoma , 2007, BJU international.

[18]  K. Ito,et al.  Impact of thrombocytosis and C‐reactive protein elevation on the prognosis for patients with renal cell carcinoma , 2006, International journal of urology : official journal of the Japanese Urological Association.

[19]  A. Jemal,et al.  Cancer Statistics, 2006 , 2006, CA: a cancer journal for clinicians.

[20]  D. McMillan,et al.  Evaluation of an inflammation‐based prognostic score in patients with metastatic renal cancer , 2006, Cancer.

[21]  Douglas G Altman,et al.  Dichotomizing continuous predictors in multiple regression: a bad idea , 2006, Statistics in medicine.

[22]  J. Lam,et al.  Novel approaches in the therapy of metastatic renal cell carcinoma , 2005, World Journal of Urology.

[23]  J. Ferlay,et al.  Global Cancer Statistics, 2002 , 2005, CA: a cancer journal for clinicians.

[24]  O. Altundag,et al.  Interleukin-6 and C-reactive protein in metastatic renal cell carcinoma. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[25]  J. Blay,et al.  Interleukin-6, interleukin-10, and vascular endothelial growth factor in metastatic renal cell carcinoma: prognostic value of interleukin-6--from the Groupe Francais d'Immunotherapie. , 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[26]  F. Mahmoud,et al.  The role of C-reactive protein as a prognostic indicator in advanced cancer , 2002, Current oncology reports.

[27]  J. Habbema,et al.  Internal validation of predictive models: efficiency of some procedures for logistic regression analysis. , 2001, Journal of clinical epidemiology.

[28]  P. Lissoni,et al.  Pretreatment serum markers and lymphocyte response to interleukin-2 therapy , 1999, British Journal of Cancer.

[29]  K. Grankvist,et al.  Serum interleukin-6 in relation to acute-phase reactants and survival in patients with renal cell carcinoma. , 1997, European journal of cancer.

[30]  J. Blay,et al.  Role of interleukin‐6 in the paraneoplastic inflammatory syndrome associated with renal‐cell carcinoma , 1997, International journal of cancer.

[31]  M. Laakso,et al.  Immunoreactive interleukin-6 and acute phase proteins as prognostic factors in multiple myeloma. Finnish Leukemia Group. , 1995, Blood.

[32]  J. Blay,et al.  Serum level of interleukin 6 as a prognosis factor in metastatic renal cell carcinoma. , 1992, Cancer research.

[33]  J V Castell,et al.  Interleukin-6 and the acute phase response. , 1990, The Biochemical journal.

[34]  H. Miyake,et al.  Prognostic prediction in patients with metastatic renal cell carcinoma treated with sorafenib based on expression levels of potential molecular markers in radical nephrectomy specimens. , 2013, Urologic oncology.

[35]  A. Jemal,et al.  Global Cancer Statistics , 2011 .

[36]  A. Jemal,et al.  Global cancer statistics , 2011, CA: a cancer journal for clinicians.

[37]  A. Paradiso,et al.  C-reactive protein: a biomarker of survival in patients with metastatic renal cell carcinoma treated with subcutaneous interleukin-2 based immunotherapy. , 2005, The Journal of urology.

[38]  A. Belldegrun,et al.  Interleukin-6 and renal cell cancer: Production, regulation, and growth effects , 2005, Cancer Immunology, Immunotherapy.

[39]  J. Robotham,et al.  The acute-phase response. , 1995, New horizons.